Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]Sulfatinib in Healthy Chinese Male Volunteers
NCT03627520Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of surufatinib in neuroendocrine tumors (NETs), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Area Under the Plasma Concentration-Time Curve from 0 to Last Measurable Concentration. Started Apr 2018; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03627520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627520.